RE:Boris interview with PabloThere is no other cannabis company growing in America and in Europe like CURA is, should schedule 3 get tied up in litigation which could very well happen and im expecting it to imo, which could prevent us from uplisting. Curaleaf could very well list on the FSE and enjoy an open market trading with out an custody issues. Major plays moving forward is our Hemp Brands, further market growth in W/S and retail in both America, EU and Australia and New Zealand. Expect new brands to be launched and new markets to be entered? Asia.. :) Boris is 4-5 moves ahead of everyone else. $CURA